...
首页> 外文期刊>Endocrine journal >Favorable Influence of Subclinical Hypothyroidism on the Functional Outcomes in Stroke Patients
【24h】

Favorable Influence of Subclinical Hypothyroidism on the Functional Outcomes in Stroke Patients

机译:亚临床甲状腺功能减退对中风患者功能结局的有利影响

获取原文
           

摘要

References(37) Cited-By(9) Subclinical hypothyroidism (SCH) is thought to have an influence on stroke outcomes. However, few reports demonstrate a favorable relationship between the two. We evaluated this association in acute ischemic stroke. From Jan 2005 to Jun 2008, 756 acute ischemic stroke patients were recruited within seven days of onset. The patients with overt hypothyroidism/hyperthyroidism or other medical conditions that may affect thyroid function were excluded. Thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels were measured within two days. Patients were divided into two groups: the SCH group (TSH 5.0 μU/mL and normal FT4 levels) and the control group. Stroke outcomes were assessed using two different criteria. In the first outcome model, favorable outcomes [I] were simply defined by modified Rankin Scale (mRS) scores (≤ 1), while the favorable outcomes [II] were defined as follows: a) a mRS score of 0, if the baseline National Institute of Health Stroke Scale (NIHSS) scores were 8, b) a mRS score of 0 or 1, if the NIHSS scores were 8-14, c) a mRS score 0-2, if the NIHSS scores were 14. The changes in mRS scores and the proportion of patients with favorable outcomes [I] or [II] at the 30th and 90th day were compared between the two patient groups. Of the 756 patients, 31 (4.1%) were patients with SCH. More patients from the SCH group showed improvement in NIHSS scores on the 30th day compared to the control group (48.4% vs. 25.3%, p=.006). In addition, the proportion of patients who exhibited favorable outcomes [I] was significantly higher in the SCH group on the 90th day (74.2% vs. 55.3%, p=.027) and that trend was seen as early as the 30th day (p=.102). Similarly, the proportion of the patients with favorable outcomes [II] was significantly greater in the SCH group both on the 30th (29.0% vs. 14.6%, p=.039) and 90th day (58.0% vs. 31.0%, p=.003). We found that acute ischemic stroke patients with SCH at admission were more likely to show favorable functional outcomes than those without SCH. We can suggest preconditioning before the stroke combined with a reduced response to stress as a possible protective mechanism.
机译:参考文献(37)被引用的文献(9)亚临床甲状腺功能减退症(SCH)对中风预后有影响。但是,很少有报道显示两者之间存在良好的关系。我们评估了急性缺血性中风的这种关联。从2005年1月至2008年6月,在发病的7天内招募了756名急性缺血性中风患者。排除明显甲状腺功能减退/甲状腺功能亢进或其他可能影响甲状腺功能的疾病的患者。在两天内测量了促甲状腺激素(TSH)和游离甲状腺素(FT4)的水平。患者分为两组:SCH组(TSH> 5.0μU/ mL,FT4水平正常)和对照组。使用两种不同的标准评估卒中预后。在第一个结果模型中,仅通过修改后的兰金量表(mRS)评分(≤1)定义好结果[I],而将好结果[II]定义如下:a)如果基线,则mRS评分为0美国国立卫生研究院卒中量表(NIHSS)得分<8,b)如果NIHSS得分为8-14,则mRS得分为0或1,c)如果NIHSS得分> 14,则mRS得分为0-2。比较两组患者在第30天和第90天的mRS得分变化和具有良好预后的患者[I]或[II]的比例。在756名患者中,有31名(4.1%)是SCH患者。与对照组相比,SCH组更多的患者在第30天的NIHSS评分有所改善(48.4%对25.3%,p = .006)。此外,SCH组在第90天表现出良好结果[I]的患者比例显着更高(74.2%vs. 55.3%,p = .027),并且这种趋势最早出现在第30天( p = .102)。同样,在第30天(29.0%比14.6%,p = .039)和第90天(SCH),在SCH组中具有良好结果[II]的患者比例显着更高(58.0%比31.0%,p = .003)。我们发现,入院时伴有SCH的急性缺血性中风患者比没有SCH的患者更有可能表现出良好的功能预后。我们可以建议在卒中之前进行预处理,并减少对压力的反应,这可能是一种保护机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号